InSpire MD

76 articles about InSpire MD

• Boston's InSpire MD Eyes $24.8 Million Series C Round

  1/26/2017

• InSpire MD Announces Pricing Of Public Offering Of Approximately $14.6 Million

  7/1/2016

• Boston's InSpire MD Names a New CEO

  6/7/2016

• InSpire MD Announces CGuard Approval In Argentina

  10/19/2015

• InSpire MD Announces Distribution Partnership Of Its CGuard Embolic Prevention System With Penumbra, Inc.

  8/6/2015

• InSpire MD's CGuard Highlighted at Clinical Presentation at EuroPCR 2015 Conference

  5/22/2015

• InSpire MD Reports Financial Results For The First Quarter Ended March 31, 2015

  5/11/2015

• InSpire MD To Report Financial Results For The First Quarter Ended March 31, 2015 On Monday, May 11th

  5/6/2015

• InSpire MD Announces MGuard Prime Approval In Brazil

  4/27/2015

• InSpire MD Announces Completion of Sales Restructuring Program

  4/15/2015

• InSpire MD Announces Completion Of Sales Restructuring Program

  4/15/2015

• InSpire MD Announces Closing Of Public Offering For Approximately $13.7 Million

  3/10/2015

• InSpire MD Seeks $13.5 Million for CGuard Stent Launch

  3/6/2015

• InSpire MD Announces Public Offering For Approximately $13.5 Million

  3/4/2015

• InSpire MD To Present At The Cowen and Company 35th Annual Healthcare Conference

  2/27/2015

• InSpire MD Shows Off New Data, CE Mark for CGuard Carotid Stent

  1/30/2015

• InSpire MD Receives CE Mark Approval For Its New CGuard RX And Announces Positive Six Month Follow-Up CARENET Trial Data At LINC 2015

  1/27/2015

• InSpire MD Reports Financial Results For The Third Quarter Ended September 30, 2014

  11/13/2014

• InSpire MD Announces Positive Results From CGuard™ CARENET Trial With 0% MACE Reported At 30 Days

  9/17/2014

• InSpire MD Reports Financial Results For The Second Quarter Ended June 30, 2014

  7/24/2014